摘要
目的探讨布-加综合征(BCS)合并肝癌(HCC)的临床特征及相关因素,从而提供治疗思路。方法回顾性分析1994年6月-2010年7月收治的1240例BCS患者中合并HCC者36例,对其影像学、实验室检查及治疗后转归进行分析。结果 BCS合并HCC主要发生在下腔静脉膜性阻塞病变中(33/36),发病平均年龄47岁,术后生存时间为14～62个月,平均生存期为32.5个月;完成随访的30例中8例BCS术后发生HCC者生存时间为BCS术后18～62个月,平均37个月;22例BCS术前诊断合并HCC者有效生存时间为BCS术后14～56个月,平均30.8个月。结论对于BCS合并HCC者应先行肿瘤TACE或TAI治疗再行BCS介入治疗。
Objective To investigate the clinical characteristics and related factors of Budd-Chiari syndrome（BCS）complicated with hepatocellular carcinoma（HCC）,in order to provide theoretical basis for clinical treatment.Methods A retrospective study was performed to analyze the imaging diagnoses,laboratory tests and follow-up results after surgery of 36 patients of BCS complicated with HCC.The study patients were selected from 1 240 patients with BCS who were hospitalized in authors＇hospital during the period from June 1994 to July 2010.Results BCS with HCC mainly occurred in membranous obstruction of inferior vena cava（MOVC）（33/36）,the average age of the onset of the disease was 46.6 years old,and the available life span after interventional or surgical operation was 14 ～ 62 months.The average survival time was 32.5 months.Eight cases who developed HCC after BCS operation had an available life span of 18 ～ 62 months（average 37 months）.Twenty-two patients with coexisting BCS and HCC before operation had an available life span of 14 ～ 56 months（average 30.8 months）.Conclusion For the treatment of BCS combined with HCC,TACE or TAI followed by interventional therapy of BCS is recommended.
出处
《介入放射学杂志》
CSCD
北大核心
2011年第3期207-209,共3页
Journal of Interventional Radiology
关键词
布-加综合征
肝癌
下腔静脉
膜性阻塞
Budd-Chiari syndrome
hepatocellular carcinoma
inferior vena cava
membranous obstruction
